Prostate Cancer Minimally Invasive Surgery Market Report, By Procedure Type (Radiation Therapy, Surgery, High-Intensity Focused Ultrasound, Chemotherapy); By Cancer Stage (Localized Prostate Cancer, Locally Advanced Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer); By End User and Regions 2025-2033

Market Overview:

"The global prostate cancer minimally invasive surgery market was valued at US$ 3.1 Billion in 2024 and is expected to register a CAGR of 4.1% over the forecast period and reach US$ 4.5 Billion in 2033."

Report Attributes	Details
Base Year	2024
Forecast Years	2025-2033
Historical Years	2021-2024
Prostate Cancer Minimally Invasive Surgery Market Growth Rate (2025-2033)	4.1%

The Prostate Cancer Minimally Invasive Surgery market focuses on advanced surgical procedures aimed at treating prostate cancer while minimizing physical trauma and recovery time for patients. Robotic assistance, laparoscopic surgery, and other image-guided procedures are commonly performed operations that offer superior precision, reduced blood loss, and less post-operative pain when compared with open surgery. Prostate cancer is one of the most common cancers in men, and in older populations very common. Demand for surgical solutions that are minimally invasive is increasing.  Patients and providers are looking for effective solutions that are safer and allow people to get back to normal faster. This is helping to drive growth in this market.

The global prostate cancer minimally invasive surgery market has witnessed substantial growth driven by technological innovations and increasing healthcare investments. The use of robotic surgical platforms in urology including da Vinci Surgical System has enhanced the dexterity, three-dimensional vision, and control of surgeons in their surgical management of complex prostatectomies. Moreover, patients are becoming more aware of benefits such as shorter hospital stays and fewer complications due to which demand is increasing. The growing number of patients with prostate cancer because of the aging populace especially in North America and Europe will further propel the market growth.  Emerging markets are also seeing rising adoption as the healthcare infrastructure improves and more minimally invasive procedures become available. This market covers robotic-assisted radical prostatectomy, laparoscopic prostatectomy, and other focal therapies that aim to preserve the prostate.

Prostate Cancer Minimally Invasive Surgery Market Trends and Drivers:

The prostate cancer minimally invasive surgery market shows several trends. Robotic-assisted surgery is the most popular use of robots in surgery. It has proven benefits and continues to be most favourite of them all. AI and machine learning innovations are aiding surgeons with better preoperative planning and intraoperative decision-making. More and more, single-port robotic systems that require fewer cuts and have better cosmetic outcomes are being developed. Tailoring surgical strategies by genetic and molecular profiling of the tumour is becoming more common. Remote surgery and telemedicine are becoming two important trends. Expert surgeons can assist or perform procedures in underserved geographic areas.

Several factors are driving robust growth in this market. The growing incidence of prostate cancer globally in older men is creating a pool of patients for minimally invasive surgeries. Advances in technology of robotic and laparoscopic procedures have made them safer, more effective and widely available. This has encouraged more companies to invest in such systems. Patients want procedures that are less painful and allow them to recover faster while spending less time in the hospital. Expanding healthcare infrastructure and rising awareness regarding the advantages of minimally invasive treatments in developing countries act as new growth drivers. Moreover, encouraging reimbursement policies and government initiatives promoting early diagnosis and modern treatments also incentivize market penetration and innovation.

Prostate Cancer Minimally Invasive Surgery Market Restraining Factors:

Despite significant potential, the prostate cancer minimally invasive surgery market faces several barriers. The expense of purchasing and sustaining robotic surgical systems can be substantial. Because of this, particularly smaller hospitals and clinics in low- and middle-income regions may be unable to afford such systems. Advanced platforms are also costly to consume with maintenance costs, and on top of that, regulatory pressure.  The surgical systems are complex, which means the surgeon requires training and experience to navigate a steep learning curve making the number of surgeons few and far between. Many regions still lack access to skilled surgeons, which is preventing the adoption of the solution.

Worries over surgery risk and long-term efficacy is another key restraint. Although minimally invasive surgeries are easier on patients than traditional approaches, and have advantages at diagnosis and treatment, complications such as nerve damage, urinary incontinence and incomplete removal of the tumour make some patients and professionals wary. Moreover, significant long-term clinical evidence comparing these interventions with open surgery is still evolving. The introduction of new devices and techniques for surgery is delayed by time-consuming and expensive regulatory and approval processes for new technologies.

Prostate Cancer Minimally Invasive Surgery Market Opportunities:

The market for minimally invasive surgery for prostate cancer will witness significant growth due to advancements and the growing global need. It will be possible to use the robotic surgical systems in smaller hospitals and clinics due the development of cheaper, smaller, and smarter systems. Innovations like augmented reality, better visualization and real-time imaging are likely to increase surgical precision and results, making minimal invasive techniques more desirable. More money is being invested in healthcare infrastructures in developing countries, allowing these advanced surgical options to become more accessible.

The growing awareness of patients and their desire for less invasive treatments offer a large potential customer base to the provider. Joint trials between the pharmaceutical industry and hospitals for customizing solutions suited to the demographic of patients and their geographical area provides healthy future opportunities. Market growth will be further propelled by improvements in insurance coverage, along with government health programs that support early diagnosis and minimally invasive treatments. As personalized medicine finds its place in surgical planning, tailor-made treatment strategies for prostate cancer will further drive innovation and uptake, making the market well-positioned for solid sustained growth in the years to come.

Prostate Cancer Minimally Invasive Surgery Market Segmentation:

By Procedure Type

• Radiation Therapy
  • External Beam Radiation Therapy (EBRT)
  • Brachytherapy (Internal Radiation)
• Robot-Assisted Radical Prostatectomy (RARP)
• Laparoscopic Radical Prostatectomy (LRP)
• Transurethral Resection of the Prostate (TURP)
• Holmium Laser Enucleation (HoLEP)
• Photoselective Vaporization of the Prostate (PVP)
• High-Intensity Focused Ultrasound (HIFU)
• Chemotherapy

Among Procedure Types, External Beam Radiation Therapy is expected to dominate the market share during the forecast period. It’s a non-invasive procedure that targets cancerous tissues exclusively, while sparing normal cells. Technological advances like intensity-modulated radiation therapy and image-guided radiation therapy continue to improve radiation cancer treatment. These systems help to leverage equipment to improve effectiveness and safety.

By Cancer Stage

• Localized Prostate Cancer (T1–T2)
• Locally Advanced Prostate Cancer (T3–T4)
• Recurrent Prostate Cancer
• Metastatic Prostate Cancer

Localized Prostate Cancer is expected to lead the market during the forecast period by cancer stage segment. Awareness in men and advanced screening have a lot to help detect prostate cancer in the early stage. Due to this, diagnosis is taking place in the early stage only. Due to this, the treatment has become effective and widely used. We offer multiple treatments at this stage that have positive outcomes. Thus, the demand is high.

By End-User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers

Hospitals are expected to hold the major share of the market by end user during the forecast period. Hospitals are the first choice for prostate cancer because they offer a whole range of surgeries, radiation, chemotherapy and rehabilitation after treatment. The whole system is staffed by specialists. Besides this, the hospitals which have better infrastructure and access to new technology get most patients.

Prostate Cancer Minimally Invasive Surgery Market, By Region:

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Italy
• Spain
• Russia
• Poland
• Benelux
• Nordic
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• South Korea
• ASEAN
• Australia & New Zealand
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• Saudi Arabia
• South Africa
• United Arab Emirates
• Israel
• Rest of MEA

The global Prostate Cancer Minimally Invasive Surgery market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is expected to lead the market, owing to the advanced health care infrastructure, high adoption of robotic-assisted surgeries, huge spending on health care for cancer treatment. Europe has the second-largest market as people are becoming aware of the minimally invasive surgical technology, government support, and investment. Asia Pacific region is witnessing fastest growing market, owing to rising cases of prostate cancer, improving healthcare access, and growing medical infrastructure especially in China and India. According to the latest analytics report by the American Cancer Society and the National Coalitions for Cancer Research, Latin America and Middle East & Africa are expected to grow steadily. This comes on the back of growing healthcare investments, and government efforts focused on improving cancer care. In summary, an upsurge in technology, as well as the preference of patients in opting for minimally invasive procedures globally, will drive growth of the surgical robot market.

Leading Companies in Global Prostate Cancer Minimally Invasive Surgery Market & Competitive Landscape:

The competitive landscape of the global Prostate Cancer Minimally Invasive Surgery market is highly competitive, with leading companies such as Intuitive Surgical, Medtronic, Johnson & Johnson, Siemens Healthineers, and Stryker Corporation driving innovation through significant investments in research and development. Companies that develop robotic surgical systems and imaging tools have become increasingly common. AI is becoming more integrated into surgical systems, in particular. Apart from innovating products, many companies are adding wide range of services including training, maintenance, and consulting to help healthcare users. Through strategic partnerships with hospitals, research institutions, and technology developers, they provide tailored, scalable solutions in multiple settings. The competition and growth of the market are further propelled by high regulatory standards and the need for prostate cancer treatments. In the ever-changing world of health, firms must constantly innovate, restrict costs, and improve hassle-free experiences to remain competitive.

These companies include:

• Intuitive Surgical, Inc.
• Medtronic plc
• Johnson & Johnson Services Inc.
• Siemens Healthineers
• Stryker Corporation
• Boston Scientific Corporation
• Levee Medical Inc.
• BK Medical Holding Company Inc.
• Olympus Corporation
• Accuray Inc.
• HealthTronics Inc.
• Mount Sinai Health System
• Dendreon Pharmaceuticals LLC
• Elekta AB

Recent Development:

• July 2025: Boston Scientific received an FDA 510(k) clearance for a label expansion for its Rezūm Water Vapor Thermal Therapy system. Because of this expansion of clearance, the system can treat a broad variety of prostate sizes (up to 150 cm3). As a result, this minimally invasive option is available for larger BPH patient populations who are often treated alongside prostate cancer.
• July 2025: Zimmer Biomet announced a definitive agreement to acquire Monogram Technologies Inc., an orthopedic robotics company. The aim of this acquisition is to add Monogram\'s autonomous robotic technologies into the Zimmer Biomet ROSA Robotics platform that offer greater precision in surgical procedures including for prostate cancer.
• May 2025: Candel Therapeutics received a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its investigational immunotherapy, CAN-2409, for newly diagnosed intermediate- to high-risk localized prostate cancer. The designation will likely speed up the development and review of this new minimally invasive therapy.
• March 2025: The FDA expanded the indication for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include earlier use in patients with metastatic castration-resistant prostate cancer. Even though it is not a surgical device, it is nevertheless an important step when it comes to minimally invasive treatment.  It represents a significant step in targeted radioligand therapy.

Prostate Cancer Minimally Invasive Surgery Market Research Scope

Report Metric	Report Details
Prostate Cancer Minimally Invasive Surgery Market Size available for the years	2022-2033
Base Year	2024
Forecast Period	2025-2033
Compound Annual Growth Rate (CAGR)	4.1%
Segment covered	By Procedure Type, Cancer Stage, End-User, and Region.
Regions Covered	North America:  The U.S. & Canada Latin America: Brazil, Mexico, Argentina, & Rest of Latin America Asia Pacific: China, India, Japan, Australia & New Zealand, ASEAN, & Rest of Asia Pacific Europe: Germany, The U.K., France, Spain, Italy, Russia, Poland, BENELUX, NORDIC, & Rest of Europe The Middle East & Africa:  Saudi Arabia, United Arab Emirates, South Africa, Egypt, Israel, and Rest of MEA
Fastest Growing Country in Europe	Germany
Largest Market	North America
Key Players	Intuitive Surgical, Inc., Medtronic plc, Johnson & Johnson Services Inc., Siemens Healthineers, Stryker Corporation, Boston Scientific Corporation, Levee Medical Inc., BK Medical Holding Company Inc., Olympus Corporation, Accuray Inc., HealthTronics Inc., Mount Sinai Health System, Dendreon Pharmaceuticals LLC, Elekta AB, among others.